Skip to main content

Archived Comments for: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Back to article

  1. Targeting EGFR, HER2 and VEGF

    Michael Hölling, Roche Pharma AG

    23 January 2009

    Dear Sir,<br><br>my first comment is just a technical one, as for the time being the provisional pdf of the article is not accessible.<br><br>Secondly, in the abstract the monoclonal antibody (MAB)Bevacizumab is erroneously described as targeting the human epidermal growth factor receptor (EGFR), while in fact it targets the vascular endothelial growth factor (VEGF) (but not its receptor). The MAB targeting the EGFR is named Cetuximab.<br><br>Yours faithfully<br>Michael Hölling

    Competing interests

    Roche: employee